[Therapeutic effectiveness of ristomycin in the visceral form of actinomycosis (experimental research)]. / Terapevticheskaia éffektivnost' ristomitsina pri vistseral'noi forme aktinomikoza (éksperimental'nye issledovaniia).

Therapeutic efficacy of ristomycin in visceral actinomycosis, a severe disease difficult for diagnosis requiring long-term complex therapy was studied on 24 rabbits. The animals were divided into 4 groups. A model of thoracal actinomycosis was developed. 7 rabbits were treated with ristomycin. The other 7 rabbits were treated with ristomycin in combination with actinolysate, a specific immune preparation. 5 rabbits were treated with actinolysate alone and the other 5 rabbits received no treatment. alone and especially in combination with actinolysate was an efficient therapeutic agent for treatment of severe visceral actinomycosis. This allowed to recommend ristomycin for clinical trials in treatment of the disease.

[Permeability of an actinomycoma for ristomycin (experimental studies)]. / K voprosu o pronitsaemosti aktinomikomy dlia ristomitsina (éksperimental'nye issledovaniia).

In vitro studies showed that ristomycin was the most active against actinomycetes causing actinomycosis as compared to benzylpenicillin, ampicillin, methicillin and lincomycin. The growth of the test microbes was inhibited by ristomycin in concentrations of 61--122 mg/ml. Since ristomycin was the most active against actinomycetes, its levels in the blood, parenchymatous organs, capsule and pus of actinomycomas of 5 rabbits infected wtih actino nycosis in the submaxillary area were determined. In the control healthy rabbit, the ristomycin levels were determined in the blood and organs. Ristomycin was administered intravenously in a single dose of 7000 mg/kg. Its concentrations in the animals were determined in 2.5 hours. The results of the experiments showed that ristomycin penetrated in therapeutic concentrations into the connective tissue capsule of actinomycoma. As for the other antibiotics tested earlier, they failed to penetrate this barrier. In 3 infected rabbits, ristomycin penetrated even the pus contained in actinomycoma. Ristomycin provides therapeutic concentrations in the disease focus and may produce a satisfactory therapeutic effect in treatment of actinomycosis.